4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 594 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, CRNX reported $8M in revenue and ($465M) in net income.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Interactive charts & full statements → Open the CRNX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $8M | $1M | $4M | $5M |
| Gross Profit | $7M | $1M | $4M | — |
| Operating Income (EBIT) | ($517M) | ($339M) | ($223M) | ($168M) |
| Net Income | ($465M) | ($298M) | ($214M) | ($164M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $11M | $6M | $0M | $1M | $0M | — |
| Gross Profit | $10M | — | — | — | $0M | — |
| Operating Income (EBIT) | ($140M) | ($134M) | ($143M) | ($129M) | ($111M) | — |
| Net Income | ($128M) | ($123M) | ($130M) | ($116M) | ($97M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.1B | $1.4B | $635M | $352M | — |
| Total Liabilities | $134M | $110M | $96M | $36M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRNX viewer.
About TickerBase · Data methodology & sources